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Abstract: Neuroendocrine neoplasms of the larynx are
rare but are the most common nonsquamous tumors of this
organ. In the past, there has been considerable confusion
about the nature and classification of these neoplasms, but the
current consensus is that there are 4 different types of laryn-
geal neuroendocrine tumors composed of paraganglioma, typi-
cal carcinoid, atypical carcinoid tumor, and small cell
neuroendocrine carcinoma. Carcinoids and small cell neuroen-
docrine carcinomas are epithelial neoplasms, whereas para-
gangliomas are of neural origin. Diagnosis is based primarily
on light microscopy and confirmed by immunohistochemistry
and electron microscopy. Precise diagnosis is essential
because the natural history, treatment, and prognosis vary
widely for the different neoplastic categories.
Typical carcinoids are very rare and are treated by wide
local excision, usually partial laryngectomy, without elective
neck dissection. Atypical carcinoid tumors are more common
and more aggressive. They are treated by partial or total laryn-
gectomy with elective or therapeutic neck dissection. Adjuvant
chemo/radiotherapy may be of benefit in some cases. Small
cell neuroendocrine carcinomas are highly aggressive and
should be considered disseminated at initial diagnosis. The
treatment is by irradiation and chemotherapy as surgery has
proven to be of a little benefit. Paragangliomas are treated by
local excision or partial laryngectomy.
It is difficult to determine the valid survival statistics for typical
carcinoids because of their rarity and confusion in the literature
with their atypical counterparts. They have a greater tendency to
metastasize, and thus a worse prognosis than was previously
believed. Atypical carcinoid tumors have a 5-year survival rate of
approximately 50%, which decreases with time. The prognosis of
small cell neuroendocrine carcinoma of the larynx is dismal, with 5-
year survival rates of 5%. The biological behavior of laryngeal
paraganglioma is generally benign and the prognosis is
excellent. VC 2009 Wiley Periodicals, Inc. Head Neck 31: 1634–
1646, 2009
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TERMINOLOGY AND CLASSIFICATION
The larynx is the most common site of cancer
in the head and neck. However, laryngeal can-
cer is listed as a ‘‘rare disease’’ by the Office of
Rare Diseases of the National Institutes of
Health. This means that laryngeal cancer
affects fewer to 200,000 people in the United
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States.1 Laryngeal cancer accounts for approxi-
mately 2% and 5% of new malignancies world-
wide every year, of which 85% to 90% are of the
squamous type.2,3
Epithelial malignancies with neuroendocrine
differentiation can occur in any organ of the body.
Laryngeal tumors with neuroendocrine morphol-
ogy are a distinct, uncommon, heterogeneous
group of neoplasms, which share specific morpho-
logic, histochemical, immunohistochemical, and
ultrastructural characteristics with prognosis de-
pendent on the tumor type. They have received
increasing attention in recent years.4 The termi-
nology is confusing and controversial and needs
standardizing, as a wide variety of names have
been used to refer to these neoplasms (Table 1).
There is no universal agreement on which termi-
nology should be used for the neuroendocrine
neoplasms of the larynx. Table 2 summarizes the
most used classifications and the relevant termi-
nology.5–14 Laryngeal neuroendocrine neoplasms
(LNN) are divided into 2 broad categories based
on their tissue of origin: epithelial and neural.
The epithelial-derived tumors, neuroendocrine
carcinomas, are subclassified into 3 subtypes:
typical carcinoid (well differentiated neuroendo-
crine carcinoma, grade I), atypical carcinoid tu-
mor (moderately differentiated neuroendocrine
carcinoma, grade II; large cell neuroendocrine
carcinoma), and small cell neuroendocrine carci-
noma (poorly differentiated neuroendocrine carci-
noma, grade III). Small cell neuroendocrine
carcinoma includes oat cell, intermediate cell,
and combined variants. The oat cell carcinoma is
composed of fusiform small cells with sparse cyto-
plasm, whereas the cells of intermediate type ex-
hibit a more abundant cytoplasm. The combined
or composite small cell neuroendocrine carcinoma
is a tumor in which there is a definite component
of small cell (oat cell or intermediate type)
Table 1. Various terms to indicate laryngeal neuroendocrine neoplasms.
Aggressive carcinoid Moderately differentiated neuroendocrine carcinoma
Anaplastic cell carcinoma Mucinous carcinoid tumor
Anaplastic small cell carcinoma Neuroendocrine adenocarcinoma
Apudoma Neuroendocrine APUD neoplasm
Argentaffinoma Neuroendocrine carcinoma
Argyrophilic cell carcinoma Neuroendocrine carcinoma of combined cell type
Atypical carcinoid Neuroendocrine carcinoma of intermediate-cell type
Atypical carcinoid tumor Neuroendocrine carcinoma of small-cell type
Atypical endocrine carcinoma Neuroendocrine carcinoma with exocrine differentiation
Atypical endocrine tumor Neuroendocrine tumor
Carcinoid Nonchromaffin paraganglioma
Carcinoid carcinoma Oat cell carcinoma
Carcinoid tumor Oncocytic carcinoid
Carcinoma with amine-precursor uptake decarboxylase cell differentiation Oncocytic carcinoid tumor
Chemodectoma Oncocytic carcinoma
Combined neuroendocrine carcinoma Oncocytic neuroendocrine carcinoma
Combined small cell carcinoma, neuroendocrine type Oncocytoid carcinoid tumor
Composite neuroendocrine carcinoma Paraganglioma
Composite small cell carcinoma Pheochromocytoma
Endocrine carcinoma Poorly differentiated neuroendocrine carcinoma
Endocrinocarcinoma Reserve cell carcinoma
Endocrinoma Small cell carcinoma
Glomus tumor Small cell carcinoma, neuroendocrine type
Grade I neuroendocrine carcinoma Small cell endocrine carcinoma
Grade II neuroendocrine carcinoma Small cell neuroendocrine carcinoma
Grade III neuroendocrine carcinoma Small cell tumor
Kultschitzky cell carcinoma Small cell undifferentiated carcinoma
Large cell neuroendocrine carcinoma Spindle-cell carcinoid tumor
Large cell undifferentiated neuroendocrine carcinoma Typical carcinoid
Malignant carcinoid Typical carcinoid tumor
Malignant nonchromaffin paraganglioma Typical endocrine tumor
Malignant paraganglioma Undifferentiated carcinoma
Mature carcinoid Undifferentiated small cell carcinoma
Medullary type of neuroendocrine carcinoma Very well differentiated neuroendocrine carcinoma
Melanotic carcinoid tumor Well differentiated neuroendocrine carcinoma
Microcytoma
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































carcinoma together with squamous cell carci-
noma and/or adenocarcinoma.15,16 The term
small cell carcinoma, particularly used for lung
cancer, is equivocal because not all small cell car-
cinomas of the larynx show neuroendocrine
differentiation.
Some authors consider the large cell neuro-
endocrine carcinoma of the larynx as a separate
entity14,17,18 using the diagnostic criteria estab-
lished for pulmonary neuroendocrine tumors.19
However, in the most recent World Health Orga-
nization classification for tumors of the larynx,
large cell neuroendocrine carcinoma is classified
together with the atypical carcinoid tumor
group.13 In 2008, Wenig20 includes the large cell
neuroendocrine carcinoma in the group of mod-
erately differentiated neuroendocrine carcinoma
(or atypical carcinoid tumor). The neural cate-
gory consists only of paraganglioma.
LNN must be further divided into primary
and secondary types, although the latter are
extremely rare and only 5 cases of small cell neu-
roendocrine carcinoma have been reported in the
literature.21 A laryngeal metastasis from a pri-
mary small cell neuroendocrine carcinoma of the
lung is distinguished from a primary LNN by
imaging studies of the lung.13 However, in rare
instances, a primary tumor (with laryngeal me-
tastasis) may be situated in other organs, includ-
ing the prostate.22 An aggressive rectal carcinoid
metastasizing to the larynx has been reported.23
The terms ‘‘neuroendocrine neoplasm or neu-
roendocrine cancer’’ are suitable for conveying a
generic concept but inadequate for diagnosis.24
Recently, the National Cancer Institute’s Sur-
veillance Epidemiology and End Results data-
base classifies ‘‘neuroendocrine tumors’’25 and
distinguishes them from ‘‘small cell tumors.’’
This terminology is confusing and inappropriate.
The diagnostic term neuroendocrine tumor is
too broad to be of practical use. The precise clas-
sification of a tumor is not only a subject of aca-
demic interest but has important clinical
implications for diagnosis, prognosis, and ther-
apy.26 Table 3 summarizes the spectrum of
LNN. They are also subdivided into benign (par-
aganglioma) and malignant (typical carcinoid,
atypical carcinoid tumor, small cell neuroendo-
crine carcinoma).
LNN have been recognized as the most com-
mon nonsquamous types of neoplasms arising in
this area. They account for less than 1% of all
laryngeal neoplasms. To date, more than 700
cases of LNN have been reported in the litera-
ture14,21,25,27 and approximately 500 publica-
tions deal with this relatively uncommon yet
intriguing family of laryngeal tumors.25,27–50
The atypical carcinoid tumor is the most fre-
quent of all LNN, followed by the small cell neu-
roendocrine carcinoma, paraganglioma, and the
typical carcinoid.
It is also difficult to determine the exact
number of each type of neuroendocrine neo-
plasm from the publications because of the dis-
parity of diagnostic criteria used. For example,
on review, almost all reported cases of malig-
nant paraganglioma were actually cases of
atypical carcinoid tumor and many cases of
typical carcinoid were also atypical carcinoid
tumors.51–53
PATHOLOGY
Typical carcinoid (Figure 1), atypical carcinoid
tumor (Figure 2), small cell neuroendocrine car-
cinoma (Figure 3), and paraganglioma (Figure
4) are distinguished from non-neuroendocrine
laryngeal neoplasms on light microscopy by
their display of neuroendocrine morphology and
on immunohistochemistry by reactivity with
neuroendocrine markers and ultrastructural evi-
dence of membrane-bound dense-core granules.
Typical Carcinoid and Atypical Carcinoid
Tumor. Grossly, these tumors vary from 0.3 to 4
cm and present as submucosal masses. They
may be polypoid, pedunculated, or nodular.
Histologically, the tumors display a variety of
features. The cells may be arranged in cords,
nests, trabeculae, or glandular patterns. The
typical carcinoid is composed of uniform and
Table 3. Spectrum of laryngeal neuroendocrine neoplasms.
Terminology Synonyms
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small polygonal cells with regular round or oval
centrally placed nuclei and granular eosinophilic
cytoplasm. The cells are separated by a fibrovas-
cular or hyalinized stroma. Mitoses, cellular
pleomorphism, and necrosis are usually absent
in the typical carcinoid. Oncocytic, oncocytoid,
mucinous and amyloid changes, focal ‘‘Zell-
ballen,’’ and rosettes may be seen in typical and
atypical carcinoids. In contrast to the typical
carcinoid, the neoplastic cells are larger and the
nuclei are often vesicular and contain prominent
nucleoli in the atypical carcinoid tumor. Typical
FIGURE 1. Typical carcinoid of the larynx of trabecular pattern composed of cuboidal cells with round to ovoid nuclei (hematoxylin-eo-
sin [H&E] stain; original magnification, 100). [Color figure can be viewed in the online issue, which is available at www.interscience.
wiley.com.]
FIGURE 2. Subepithelial atypical carcinoid tumor of the larynx. This is a characteristic pattern of the lesion (H&E stain, original magni-
fication, 100). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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carcinoid has fewer than 2 mitoses per mm2 (10
high-power fields) without necrosis, whereas
atypical carcinoid tumor has 2 to 10 mitoses per
mm2 and/or necrosis.
The tumors are positive for the most sensi-
tive and specific neuroendocrine markers (in
particular for synaptophysin, chromogranin, and
CD56), neuropeptide markers (in particular for
calcitonin and somatostatin), and almost always
for low-molecular-weight cytokeratins as well as
other epithelial markers (carcinoembryonic antigen
[CEA] and epithelial membrane antigen [EMA]).
FIGURE 4. Paraganglioma of the larynx (H&E stain, original magnification, 100). [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
FIGURE 3. Small cell neuroendocrine carcinoma of the larynx. The tumor is composed of uniform small cells with hyperchromatic
nuclei and scanty cytoplasm (H&E stain, original magnification, 100). [Color figure can be viewed in the online issue, which is avail-
able at www.interscience.wiley.com.]
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Small Cell Neuroendocrine Carcinoma. Grossly,
the tumors usually arise submucosally and may
vary in size from 0.5 cm to a size of 4 to 5 cm.
Histologically, the neoplasm can be divided into
3 types. These are oat cell, intermediate, and
combined. The oat cell type is composed of
sheets of small cell with hyperchromatic nuclei
and scant cytoplasm. Occasionally, the cells
form interconnecting ribbons. Cell necrosis and
mitotic activity are frequent. Rosette formation
may be seen. In the intermediate cell type, the
growth pattern is similar, but the cells are
slightly larger, more polygonal, spindle shaped,
or fusiform. The cytoplasm is more prominent
than in the oat cell type. In the combined type
(the rarest of the 3 types), the tumor is a mix-
ture of small cell neuroendocrine carcinoma
with another tumor, usually squamous cell car-
cinoma or adenocarcinoma.
Small cell neuroendocrine carcinoma may be
immunoreactive with cytokeratins, EMA, CEA,
and with general neuroendocrine markers,
including chromogranin, CD56, CD57, synaptho-
physin, neuropeptides, including calcitonin,
somatostatin, adrenocorticotropic hormone, bomb-
esin, and serotonin. In addition, small cell neuro-
endocrine carcinoma may be positive for thyroid
transcription factor-1. Table 4 summarizes the cri-
teria for histologic diagnosis of LNN. Table 5
shows the comparison of the immunohistochemical
findings of LNN.7,27
Paraganglioma. Grossly, this tumor has been
described as a red or blue submucosal mass of 1
to 6 cm in size. The average tumor is 2 to 3 cm
in diameter. On sectioning, it is firm and rub-
bery with a red or brown cut surface. Areas of
hemorrhage may be seen and streaks of fibrous
tissue are often identified.
Histologically, the tumor is composed of 2 cell
types, chief cells and sustentacular cells. Chief
cells are polygonal cells with inconspicuous
nuclei and eosinophilic cytoplasm. There is some
pleomorphism, but mitoses are not usually seen.
These cells are arranged into a characteristic,
but not pathognomonic alveolar or ‘‘Zellballen’’
pattern. Around the edge of the ‘‘Zellballen’’ is
the second type of cell. These are the slender,
spindle-shaped sustentacular cells. This tumor is
highly vascular. A dense fibrous capsule can be
frequently seen surrounding the tumor. Vascular
invasion, perineural involvement, and necrosis
are infrequent and do not necessarily indicate
aggressive or malignant behavior.51
Table 4. Criteria for the histologic diagnosis of laryngeal
neuroendocrine neoplasms.
Typical carcinoid
Subepithelial lesion without ulceration of the mucosa
Trabecular and/or organoid pattern
Glandular and/or squamous differentiation
Oncocytic and oncocytoid changes may be present
Mucinous changes may be present
Stromal amyloid may be present
Squamous nests may be seen
Rosettes may be present
Less than 2 mitoses per 2 mm2 (10 HPFs)
Sustentacular cells may be present
Focally ‘‘Zellballen’’ pattern may be seen
Fibrovascular or hyalinized connective tissue stroma
Absence of necrosis, mytoses, cytological pleomorphism
Atypical carcinoid tumor
Subepithelial lesion without ulceration of the mucosa
Trabecular and/or organoid pattern
Glandular and/or squamous differentiation
Oncocytic and oncocytoid changes may be present
Mucinous changes may be present
Stromal amyloid may be present
Squamous nests may be present
Rosettes may be present
2 to 10 mitoses per 2 mm2 (10 HPFs)
Sustentacular cells may be present
Necrosis (often punctuate)
Focally ‘‘Zellballen’’ pattern may be present
Cysts with intracystic papillary like projections of tumor cells
may be seen
Large cells with abundant eosinophilic, finely granular
cytoplasm with vesicular nuclei and prominent nucleoli
Small cell neuroendocrine carcinoma
Subepithelial lesion with ulceration of the mucosa
Ribbon-like formation
Glandular differentiation rarely seen
Presence of amyloid may be observed
Squamous nests may be present
Rosette pattern
Brisk mitotic activity (11 or greater per 2 mm2 [10 HPFs])
Azzopardi effect
Prominent crush phenomenon
Small oval to spindle-shaped cells with hyperchromatic
granular (or ‘‘salt and pepper’’) chromatin, scant/absent
cytoplasm, absent/inconspicuous nucleoli, nuclear
molding, mytoses, apoptosis
Frequent necrosis (often large zones)
Neutropism and angioinvasion is commonly seen
High nuclear to cytoplasmic ratio
In the combined cell type, there is a simultaneous
component of squamous cell carcinoma and/or
adenocarcinoma.
Paraganglioma
Subepithelial lesion without ulceration of the mucosa
Organoid pattern with aggregation of chief cells in the




Mitoses and necrosis are infrequent
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Immunohistochemically, the chief cells are
positive for all the general neuroendocrine
markers such as chomogranin, synaptophysin,
CD57, and neuropeptide markers, including gal-
anin and somatostatin). They do not stain with
epithelial markers (cytokeratin, CEA, EMA) or
with calcitonin and bombesin and this supports
the diagnosis. Sustentacular cells are stained by
antibodies to S-100 protein and glial fibrillary
acidic protein. The chief cells are S-100 protein
and glial fibrillar acid protein negative.
IDENTIFICATION
The first laryngeal neuroendocrine neoplasm of
neural type was identified in 1955 by Blanchard
and Saunders,54 whereas only recently laryn-
geal neuroendocrine carcinomas have been rec-
ognized. In particular, the first atypical
carcinoid tumor was reported in 1969 by Gold-
man et al.55 The identification of LNN is a step-
wise process. First, tumors must be recognized
as neuroendocrine by the presence of neuroen-
docrine morphology on conventional light mi-
croscopy including organoid nesting, peripheral
palisading of tumor nests, trabeculae, glandular
differentiation, rosette formation and ‘‘crush ar-
tifact,’’ Azzopardi phenomenon, ‘‘Zellballen’’
arrangement, and other histologic features.
Once a tumor is considered to be neuroendo-
crine in consideration of morphologic findings, it
is important to distinguish between typical car-
cinoid, atypical carcinoid tumor, small cell neu-
roendocrine carcinoma, and paraganglioma. The
diagnosis of neuroendocrine neoplasm requires
the presence of both neuroendocrine morpholo-
gies by light microscopy and demonstration of
neuroendocrine differentiation by immunohisto-
chemistry or electron microscopy. However, the
diagnosis of laryngeal small cell neuroendocrine
carcinoma is predominately a morphologic diag-
nosis, as in a limited number of cases this tumor
is negative for all neuroendocrine markers. In
the lung, the absence of staining for multiple neu-
roendocrine markers occurs in 10% to 15% of
cases.56 The presence of neurosecretory granules
preferentially located in the periphery of the cyto-
plasm, as observed by electron microscopy, are
used to confirm the histologic diagnosis in the ab-
sence of a positive immunohistochemical profile
for neuroendocrine markers. Distinguishing the
type of LNN is largely a morphologic exercise.
Immunohistochemistry does not serve as a sub-
stitute but as a valid adjuvant in the light evalua-
tion of the morphological criteria of these
neoplasms.57 Tumors of the larynx with neuroen-
docrine differentiations have widely varying
prognosis and response to therapy; thus accurate
histologic identification is essential.
LNN can be confused with other neoplasms
such as adenocarcinoma not otherwise defined,
acinic cell carcinoma, basaloid squamous cell car-
cinoma, solid type of adenoid cystic carcinoma,








Cytokeratin þ þ þ 
Epithelial membrane antigen þ þ þ 
Carcinoembryonic antigen þ þ þ 
Calcitonin þ þ þ/ 
Chromogranin þ þ þ þ
Synaptophysin þ þ þ þ
CD57 (Leu 7) þ þ þ þ
CD56 þ þ þ þ
Neuron-specific enolase þ þ þ þ
Protein gene product 9.5 þ þ þ þ
Galanin    þ
Bombesin þ þ þ 
Somatostatin þ þ þ þ
Serotonin þ þ þ þ
Thyroid transcription factor-1  þ/ þ/ 
S-100 protein  *  þ†
Glial fibrillary acidic protein    þ†
Reprinted as adapted, with permission from Ferlito et al, Oral Oncol, 2006;42:770–778, VC Elsevier.
*20% positivity in the Wenig et al’s series.7
†Positivity only in the sustentacular cells.
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poorly differentiated squamous cell carcinoma,
undifferentiated carcinoma, amelanotic malig-
nant melanoma, medullary thyroid carcinoma,
lymphoma, hemangiopericytoma, and others.26
TREATMENT OF NEUROENDOCRINE NEOPLASMS
Typical Carcinoid. Surgical excision is the treat-
ment of choice for typical carcinoid of the lar-
ynx.58,59 Conservation surgery, particularly
supraglottic subtotal laryngectomy, may be suit-
able but large tumors require total laryngec-
tomy. Neck dissection is not indicated in view of
the usual absence of lymph node metastases.53
Moreover, irradiation and chemotherapy have
been found to be ineffective.27
Atypical Carcinoid Tumor. The mainstay of treat-
ment for atypical carcinoid tumor of the larynx
is surgical excision.27,58 Partial or total laryn-
gectomy may be performed depending on the
site and extent of the primary tumor. As most
tumors are supraglottic in location, supraglottic
laryngectomy is often the procedure of choice.
Endoscopic laser surgery has been employed
instead of an external approach for supraglottic
atypical carcinoid tumor,60,61 although 1 tumor,
involving the aryepiglottic fold, recurred requir-
ing a second, successful laser resection with
wider margins.61 As perineural extension may
exist peripheral to the main tumor mass, wide
resection beyond clinically detectable cancer
margins is indicated.62 Neural spread is often
discontinuous, and apparently negative margins
determined by frozen section may prove positive
when permanent sections are obtained.
Elective neck dissection appears to be war-
ranted in view of the high incidence of both
early cervical metastasis and subsequent
involvement of cervical nodes.53,63 The dissec-
tion of sublevel IIA and level III only is
adequate for elective surgical treatment of the
neck in supraglottic and glottic tumors.64 Bilat-
eral selective neck dissection should also be used
therapeutically for mobile metastatic disease.
Although earlier literature indicated that
radiation and chemotherapy employed preopera-
tively, postoperatively, or as a primary modality
were ineffective in the management of this
malignancy,62,63 Gillenwater et al,65 in a retro-
spective review of patients treated at The Uni-
versity of Texas M. D. Anderson Cancer Center,
reported that a few patients with atypical carci-
noid tumors responded to these modalities, sug-
gesting that a combined approach may be
beneficial, at least for some patients.
Small Cell Neuroendocrine Carcinoma. It is gen-
erally agreed that surgery alone or in combina-
tion with radiation does not improve local tumor
control and is not the initial treatment of
choice.58,66,67 Total laryngectomy may control
the primary tumor, but the resultant loss of
voice is not justifiable in the face of other modal-
ities that may offer primary tumor control.66
Baugh et al67 reviewed the various modalities
that have been used to treat this cancer.
Although radiation alone did not improve sur-
vival, it was successful in controlling the tumor
at the primary site. Adjuvant chemotherapy
appeared to prolong the median survival among
patients from 11 to 19 months. The combination
of primary radiation therapy and adjuvant
chemotherapy resulted in median patient sur-
vival of 55 months, representing significantly
longer survival than with any other treatment
regimen.
The commonly used chemotherapeutic agents
are cyclophosphamide, doxorubicin, vincristine,
methotrexate, and lomustine. A 9- to 18-month
period of treatment is usually suggested.66,67 Re-
sistance to chemotherapy represents an impor-
tant indicator of poor prognosis. The recurrence
is usually generalized and the results of any
therapy are poor. Nevertheless, palliative chem-
otherapy may be warranted even under these
circumstances, as some improvement in the
quality and length of life may be achieved.
As the chemotherapeutic agents commonly
employed do not penetrate the blood–brain bar-
rier, prophylactic cranial irradiation has been
suggested as part of the management of this
cancer.68–70 However, Ferlito and Rinaldo21 have
pointed out that central nervous system metas-
tasis occurs in only 7.7% of patients with laryn-
geal small cell neuroendocrine carcinoma, and
this occurs usually as a preterminal event. There-
fore, such elective treatment is not indicated.
The role of surgery in the management of
small cell neuroendocrine carcinoma of the lar-
ynx is extremely limited. Instances in which
partial laryngectomy would likely be adequate
to extirpate this aggressive malignancy are
extremely uncommon, and most authors feel
that such management of even early lesions is
best avoided.21,58
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Paraganglioma. Laryngeal paragangliomas are
almost invariably benign and should be treated
as such. Surgery is preferable to radiation for
paragangliomas arising in the larynx as cure
can be easily achieved without loss of laryngeal
function.71 Partial laryngectomy remains the
mainstay of treatment.72 Although transoral
laser microsurgery has been used successfully in
at least 1 reported case,73 laser surgery is typi-
cally not recommended because of the vascular
nature of these tumors. Excision of the upper
half of the thyroid cartilage is typically
employed to expose and achieve complete resec-
tion of supraglottic tumors while preserving
phonation and deglutition. When possible, an
extramucosal excision of tumors arising in the
paraglottic and/or supraglottic space is pre-
ferred.58 The generally small size and consistent
blood supply of the laryngeal paraganglioma
make preoperative angiography and emboliza-
tion unnecessary. Ligation of the arterial blood
supply at the time of surgery will minimize
introperative blood loss.
A small number of paragangliomas are not
supraglottic and may present as transventricu-
lar or infraglottic tumors.42,74–77 These lesions,
particularly if large, present a therapeutic chal-
lenge, but as they are benign, conservative pro-
cedures such as local excision via larygofissure,
with or without cricoid split, are usually per-
formed and often successful.
Most patients require temporary tracheos-
tomy after surgery due to edema and potential
for airway compromise. With appropriate clini-
cal suspicion and the use of modern imaging
techniques, laryngeal paragangliomas can be
routinely diagnosed and treated with the preser-
vation of laryngeal function.71
PROGNOSIS
The clinical course of laryngeal typical carcinoid
is not indolent, as was believed in the past, and
distant metastases, which involve the liver and
cause death, have occurred.78 Soga et al79
observed that 33.3% of 42 patients with typical
carcinoid of the larynx also developed metasta-
ses. Batsakis et al80 reported distant metastases
in 4 of 13 (30.7%) reported cases of typical carci-
noid. Wenig and Gnepp81 reported a case of typi-
cal carcinoid of the larynx associated with
carcinoid syndrome, which developed subse-
quently to the appearance of multiple liver me-
tastases. The 5-year survival rate for typical
carcinoid of the larynx was 48.7% in a large se-
ries as recently reported.82 The low survival
rate is probably due to several cases of atypical
carcinoid tumor that had been erroneously clas-
sified as typical carcinoid.27 The clinical behav-
ior of an atypical carcinoid tumor is aggressive
and is more aggressive when the metastatic
index is high. An unfavorable course is observed
when there are lymphatic emboli or when the
Ki67 index is higher than 5%.28 Soga et al79
described finding metastases in 66.7% of 199
cases of atypical carcinoid tumor of the larynx.
Cervical lymph node metastases are often pres-
ent. Other sites of metastases include
bone, skin, subcutaneous tissues, distant lymph
nodes, lung, mediastinum, liver, heart, pan-
creas, diaphragm, peritoneum, gastrointestinal
tract, prostate, breast, brain, dura mater,
pleura, testicle, and muscle. Death has usually
resulted from distant metastases and not from
local or regional recurrence. The survival rate is
48% at 5 years and 30% at 10 years.83 In 2003,
Soga82 reported that the 5-year survival rate for
this tumor was 46.7%. In 2007, Ebihara et al34
collected 33 cases of laryngeal carcinoid (94%
atypical carcinoid tumors and 6% typical carci-
noids) in Japan. The 3-, 5-, and 10-year survival
rates of the patients were 58.5%, 36.5%, and
12.2%, respectively. Thus, the survival rate
decreased slowly with the passage of time. Four
cases of carcinoid syndrome have been reported
in association with atypical carcinoid tumor of
the larynx and reportedly all patients died.84
The prognosis of small cell neuroendocrine
carcinoma of the larynx is very poor,85 and the
clinical course is rapidly fatal. It is the most
lethal tumor of the larynx. More than 90% of
patients with this tumor develop metastatic dis-
ease.86 The most common sites of metastatic
spread of this very aggressive neoplasm are the
cervical lymph nodes, liver, lung, bones, and
bone marrow. As with small cell lung cancer,
small cell neuroendocrine carcinoma of the lar-
ynx should be regarded as a systemic disease.27
In a review by Gnepp et al,87 73% of patients
with laryngeal small cell neuroendocrine carci-
noma died of disease with widespread metasta-
ses, with a mean survival time of 9.8 months
(range, 1–26 months). The 2- and 5-year sur-
vival rates are 16% and 5%, respectively.86 In
2004, Soga et al79 reported a 5-year survival
rate of 7.7%. These survival rates are similar to
Neuroendocrine Neoplasms of the Larynx HEAD & NECK—DOI 10.1002/hed December 2009 1643
those for small cell lung cancer85 and did not
correlate with the tumor size.86 This phenom-
enon has been attributed to the prominent vas-
cular invasion typically present even in small
tumors.87 The prognosis of combined small cell
neuroendocrine carcinoma of the larynx is simi-
lar to that of a pure small cell neuroendocrine
carcinoma.21 A 2008 publication, using the
National Cancer Institute’s Surveillance and
End Results database, found 5-year survival
rates for glottic and supraglottic small cell carci-
noma of 15% and 24.1%, respectively.25 This dif-
ference may be due to the diagnostic criteria
employed. Different paraneoplastic syndromes,
including Schwartz-Bartter, Cushing, and
Eaton-Lambert syndromes, have been reported
in 5 cases of small cell neuroendocrine carci-
noma of the larynx and reportedly all patients
died.84
The biological behavior of laryngeal paragan-
glioma is almost exclusively benign. Malignant
behavior has been reported in several cases, but
critical reviews of the literature have accepted
only 1 case of metastatic paraganglioma of
the larynx.51–53,71,88,89 No paraneoplastic syn-
dromes have been reported in association with
paraganglioma.84
CONCLUSIONS
LNN constitute a variety of rare neoplasms of the
larynx that have had numerous names and clas-
sification in the past, but are currently classified
as typical carcinoid, atypical carcinoid tumor,
small cell neuroendocrine carcinoma, and para-
ganglioma. It is most important to classify each
case correctly as the clinical course, treatment,
and prognosis varies greatly according to the
diagnosis. Typical carcinoids are more aggressive
than previously believed and metastasize in
about 1/3 of cases. They are treated by partial or
total laryngectomy without neck dissection.
Atypical carcinoid tumors metastasize to re-
gional nodes as well as distantly. They are
treated surgically by partial or total laryngec-
tomy with elective or therapeutic neck dissec-
tion. Small cell neuroendocrine carcinomas are
highly aggressive. Treatment is by irradiation
and chemotherapy. The survival rates are simi-
lar to those for small cell lung cancer. Laryngeal
paragangliomas should be treated by local exci-
sion or partial laryngectomy. The prognosis is
excellent.
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